Displaying results 109 - 120 of 159
General Hepatology
Determining the prevalence and characterizing the associated factors and health outcomes related to Metabolic dysfunction-associated steatotic liver disease (MASLD) and Metabolic dysfunction-associated steatohepatitis (MASH) in patients with type 2 diabet

Determining the prevalence and characterizing the associated factors and health outcomes related to Metabolic dysfunction-asso...

ePosters
View
General Hepatology
Prevalence of multifactorial steatotic liver disease: Why it should be included in the international classification of steatotic liver disease

Prevalence of multifactorial steatotic liver disease: Why it should be included in the international classification of steatot...

ePosters
View
General Hepatology
The pattern of liver enzymes enhances the prognostic value of the Fibrosis-4 index for patients with metabolic dysfunctionassociated steatotic liver disease

The pattern of liver enzymes enhances the prognostic value of the Fibrosis-4 index for patients with metabolic dysfunctionasso...

ePosters
View
General Hepatology
JAK2 inhibitor ruxolitinib ameliorates portal hypertension associated with metabolic dysfunction-associated liver disease

JAK2 inhibitor ruxolitinib ameliorates portal hypertension associated with metabolic dysfunction-associated liver disease

ePosters
View
General Hepatology
Arsenic as a risk factor for hepatocellular carcinoma (HCC) risk among patients with metabolic associated liver disease (MASLD)

Arsenic as a risk factor for hepatocellular carcinoma (HCC) risk among patients with metabolic associated liver disease (MASLD...

ePosters
View
General Hepatology
Differences in gut microbiome diversity in patients with metabolic dysfunction-associated steatotic liver disease associate with response to faecal microbiota transplant

Differences in gut microbiome diversity in patients with metabolic dysfunction-associated steatotic liver disease associate wi...

ePosters
View
General Hepatology
Fibrosis stage versus fibrosis-4 score for predicting clinical outcomes in metabolic dysfunction-associated steatotic liver disease, and evaluation of healthcare resource utilization and associated costs

Fibrosis stage versus fibrosis-4 score for predicting clinical outcomes in metabolic dysfunction-associated steatotic liver di...

ePosters
View
General Hepatology
Advanced metabolic-dysfunction associated steatotic liver disease fibrosis: Low number-needed-to screen in multiple lines of care

Advanced metabolic-dysfunction associated steatotic liver disease fibrosis: Low number-needed-to screen in multiple lines of c...

ePosters
View
General Hepatology
Association of newly-onset dyslipidemia and metabolic dysfunction-associated steatotic liver disease (MASLD) among chronic hepatitis B patients with antivirus treatment in China

Association of newly-onset dyslipidemia and metabolic dysfunction-associated steatotic liver disease (MASLD) among chronic hep...

ePosters
View
General Hepatology
Association between sarcopenia and coronary atherosclerosis in metabolic dysfunction-associated steatotic liver disease

Association between sarcopenia and coronary atherosclerosis in metabolic dysfunction-associated steatotic liver disease

ePosters
View
General Hepatology
Lifestyle modification and cognitive behavioral therapy in the treatment of MASLD

Lifestyle modification and cognitive behavioral therapy in the treatment of MASLD

ePosters
View
General Hepatology
Natural history of metabolic dysfunction-associated steatotic liver disease: A 5-year community-based follow-up study

Natural history of metabolic dysfunction-associated steatotic liver disease: A 5-year community-based follow-up study

ePosters
View
Displaying results 109 - 120 of 159